PRKCG抗体;PRKCG Antibody—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Hela cells, human liver cancer tissue, Primary antibody: P07532(PC Antibody) at dilution 1/100, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

The PRKCG antibody targets protein kinase C gamma (PKCγ), a member of the protein kinase C (PKC) family, which plays critical roles in signal transduction and cellular regulation. Encoded by the PRKCG gene, PKCγ belongs to the classical PKC subfamily (cPKC), characterized by its dependence on calcium ions and diacylglycerol (DAG) for activation. It is predominantly expressed in the central nervous system, particularly in cerebellar Purkinje cells and select neuronal populations, where it regulates synaptic plasticity, neuronal development, and memory formation. Structurally, PKCγ contains regulatory (C1 and C2 domains) and catalytic kinase domains, enabling its involvement in phosphorylation-dependent signaling cascades.

Mutations in PRKCG are linked to spinocerebellar ataxia type 14 (SCA14), a neurodegenerative disorder marked by progressive motor coordination deficits. PRKCG antibodies are widely used in research to study PKCγ expression, localization, and function in both physiological and pathological contexts. They enable techniques like Western blotting, immunohistochemistry, and immunofluorescence to investigate PKCγ's role in neurological diseases, cancer, and immune responses. Clinically, these antibodies aid in diagnosing SCA14 and understanding molecular mechanisms underlying PKCγ-associated pathologies. Their specificity and reliability make them essential tools for dissecting PKC signaling pathways and developing targeted therapies.